Mean | Std. Deviation | |
---|---|---|
Age | 64.2 | 9.2 |
Disease duration | 6.8 | 4.5 |
Sex (male/female) n | 90 | 88 |
Wearing off (+/−) n | 58 | 120 |
Dyskinesia (+/−) n | 42 | 136 |
Levodopa mg | 344.1 | 202.8 |
Levodopa (+/−) n | 154 | 24 |
Dopamine agonist levodopa equivalent dose (mg) [12] | 166.3 | 121.1 |
Total levodopa equivalent dose (mg) [12]a | 592.0 | 317.6 |
Unified Parkinson’s Disease Rating Scale | ||
Part I | 0.7 | 1.2 |
Part II | 5.6 | 3.9 |
Part III | 15.7 | 8.4 |
Part IV | 1.7 | 2.2 |
Total | 23.7 | 11.8 |
Modified Hoehn and Yahr stage | 2.1 | 0.6 |
Parkinson’s disease Questionnaire-39 | ||
Mobility | 10.4 | 9.1 |
Activities of daily living | 5.2 | 5.1 |
Emotional well-being | 6.0 | 4.4 |
Stigma | 3.2 | 2.8 |
Social support | 1.4 | 1.9 |
Cognitions | 4.0 | 3.0 |
Communication | 1.7 | 2.2 |
Body discomfort | 2.5 | 2.6 |
Total | 34.4 | 24.2 |